Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

topotecan
refractory neuroblastoma
bone marrow procedure
cyclophosphamide
  • 7 views
  • 26 Mar, 2021
  • 44 locations
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended

avid
iobenguane
tumor cells
bone marrow procedure
topotecan
  • 158 views
  • 02 Feb, 2021
  • 15 locations
Activity Study of Bevacizumab With Temozolomide Irinotecan for Neuroblastoma in Children

-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of

neutrophil count
filgrastim
dinutuximab
bone marrow disease
topotecan
  • 57 views
  • 24 Jan, 2021
  • 10 locations
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

azacitidine
solid tumour
topotecan
venetoclax
dexamethasone
  • 263 views
  • 28 Jan, 2021
  • 39 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

brainstem tumor
neutrophil count
tumor cells
nervous
131i-mibg
  • 990 views
  • 10 Apr, 2021
  • 114 locations
MIBG for Refractory Neuroblastoma and Pheochromocytoma

This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and …

interleukin-2
iobenguane
total body irradiation
biologics
antibody therapy
  • 5 views
  • 29 Jan, 2021
  • 1 location
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

avid
neutrophil count
eflornithine
renal function
iobenguane
  • 0 views
  • 26 Jan, 2021
  • 12 locations
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of ch14.18 and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with ch14.18, for treatment of children with …

neutrophil count
iobenguane
tumor cells
monoclonal antibody ch14.18
monoclonal antibodies
  • 18 views
  • 29 Jan, 2021
  • 11 locations
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology. A promising way to further improve outcome in this disease appears to be the development of adjuvant therapeutic strategies. In this research the anti-GD2 antibody, which is a standard treatment, is to …

avid
neutrophil count
dinutuximab
pulmonary function test
renal function
  • 10 views
  • 26 Jan, 2021
  • 3 locations
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatment at this time, patients are …

liver disease
breast cancer
tumor cells
fludarabine
metastatic uveal melanoma
  • 7 views
  • 27 Jan, 2021
  • 2 locations